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ABSTRAK 
 
Kekebalan terhadap chloroquine telah mengakibatkan peningkatan 
kematian dan morbiditi daripada penyakit malaria P. falciparum. Ketiadaan 
vaksin yang berkesan mengakibatkan terapi malaria bergantung pada kombinasi 
ubat alternatif seperti Mefloquine dan Artesunate dan tahap kekebalan terhadap 
ubat-ubat alternatif tersebut kerap meningkat. Adalah diketahui bahawa agen 
perencat glycoprotein P berupaya menghalang kekebalan sel barah terhadap 
pelbagai ubat melalui pencegahan effluks ubat anti-barah oleh glycoprotein P. P. 
falciparum juga didapati membentuk homolog glycoprotein P (pgh1) pada 
membrannya dan Verapamil dan pengujakimia lain (contohnya: antihistamin) 
boleh mengekang kekebalan Chloroquine. Oleh demikian, adalah dicadangkan 
bahawa agen perencat glycoprotein P boleh berfungsi sebagai pengujakimia 
yang berkesan kerana pengangkut dalam kelas "ABC superfamili" kerap 
mempunyai substrat dan agen perencat yang serupa. 
Dua agen perencat p-gp (rifampicin dan omeprazole) diuji dalam kajian ini 
secara in vitro dan in vivo dengan matlamat menghalang kekebalan terhadap 
Chloroquine. 
P. falciparum yang sensitif terhadap chloroquine and yang kebal terhadap 
chloroquine (strain HB3, TM90C2B, Dd2) dicairkan daripada keadaan sejukbeku 
dan dikultur dalam media RPMI 1640, sel darah merah 'O' dan serum pada 37˚C 
 ْ◌b erdasarkan protocol Trager-Jansen yang diubahsuai. Chloroquine dicairkan 
secara berperingkat dan diuji bersama Rifampicin/Omeprazole dalam nisbah 
 17
kepekatan yang berbeza-beza dalam plat micro ELISA steril yang mengandungi 
kultur parasit. Selepas tempoh inkubasi yang tertentu, plat ujian dikeluarkan and 
keputusan dicapai melalui kaedah kematangan schizont atau melalui 
pergabungan hipozantina radioaktif dengan DNA parasit. 
P. berghei (strain NK65, ANKA) juga dicairkan dan disuntik ke dalam 
ruang peritoneal tikus Swiss Albino yang berumur 6-7 minggu. Bila virulen 
menjadi stabil, pelbagai amaun Chloroquine diberikan bersama Rifampicin atau 
Omeprazole mengikut regim Peter's selama 4 hari berturut-turut. Peratusan 
parasitemia diketahui melalui calitan nipis darah tikus pada sisip kaca. Hari 
parasit muncul kembali dalam darah dan hari kematian tikus juga dicatat. 
Kajian in vitro menunjukkan bahawa Rifampicin bersifat amat antagonis 
terhadap chloroquine untuk strain HB3 dan TM90C2B (FIC purata >2). Takat 
antagonis berkurangan apabila tempoh inkubasi drug bersama parasit 
dipanjangkan ke 72 jam. Keputusan ini disokong dalam kajian in vivo di mana 
tikus yang diberi rifampicin serta chloroquine menunjukkan parasit muncul 
kembali dengan lebih awal dan kematian tikus meningkat. 
Kajian in vitro Omeprazole menunjukkan ia juga bersifat antagonis 
terhadap Chloroquine tetapi tidak seteruk berbanding interaksi Rifampicin-
Chloroquine. Pada dos harian 5-20 mg/kg, kajian in vivo mendedahkan bahawa 
Omeprazole mengurangkan kematian tikus dalam tempoh pemerhatian sebulan 
dan melambatkan kemunculan semula parasit dalam darah, tetapi keputusan 
tersebut tidak mencapai tahap signifikan bila diuji dengan statistik. Tiada kesan 
yang nyata pada kadar penurunan parasitemia.  
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Rifampicin bersifat amat antagonis terhadap chloroquine secara in vitro 
and in vivo. Maka, kombinasi Rifampicin-Chloroquine patut dielakkan dalam 
amalan klinikal. Kemungkinan bahawa penggunaan Rifampicin dalam pesakit TB 
yang juga menghidap malaria boleh menyebarluaskan kekebalan Chloroquine 
kerana pemanjangan tempoh untuk membasmi parasit. 
 Kedua-dua inhibitor p-glycoprotein tidak merupakan pengujakimia yang 
berkesan buat gejala kekebalan chloroquine. Maka mekanisme kekebalan 
parasit malaria terhadap Chloroquine perlu diselidik semula untuk menjumpai 
agen yang lebih sesuai untuk mengekang kekebalan Chloroquine. 
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ABSTRACT 
 
 
Chloroquine resistance has resulted in a resurgence of morbidity and 
mortality from P. falciparum malaria. The lack of an effective vaccine forces 
dependence on alternative drug combination therapies based on mefloquine or 
artesunate, of which the incidence of multidrug resistance is steadily rising. P-
glycoprotein inhibitors reverse multidrug resistance in tumour cells by preventing 
efflux of anti-neoplastic drugs by p-glycoprotein, an ATP-binding cassette 
transporter (ABC). P. falciparum was also found to possess a p-gp homologue 
(pgh1) and that verapamil and other chemosensitizers (antihistamines, 
antidepressants) are able to reverse chloroquine resistance. It was postulated 
that potent p-gp inhibitors would be effective chemosensitizers as transporters of 
the ABC superfamily frequently share similar substrates and inhibitors. 2 known 
p-gp inhibitors (rifampicin and omeprazole) are assayed in this study, in vitro and 
in vivo, aiming to achieve chemoreversal of chloroquine resistance. 
Chloroquine-sensitive and chloroquine-resistant P. falciparum (HB3, 
TM90C2B, Dd2 strains) were thawed and maintained in continuous culture using 
RPMI 1640 media, ‘O’ RBCs and pooled serum at 37°C using a modified Trager-
Jansen candle jar protocol. Serial two fold dilutions of chloroquine and assayed 
chemosensitizers were performed on sterile ELISA microplates in checkerboard 
pattern to achieve different drug ratios in respective culture wells.  
After a fixed incubation period, test plates were harvested and results obtained 
by assessing schizont maturation or incorporation of radioactive hypoxanthine. 
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P. berghei (NK65, ANKA strains) were thawed and injected 
intraperitoneally into naïve Swiss Albino mice (6-7 weeks old). Upon stabilization 
of virulence, various chloroquine doses combined with rifampicin or omeprazole 
were administered intraperitoneally following a standard Peters’ consecutive 4-
day treatment regime. Percentage parasitemia was assessed by thin smears of 
tail blood. Day of recrudescence and survival within a month were also noted. 
In vitro rifampicin showed marked antagonism when combined with 
chloroquine against P. falciparum strains HB3 and TM90C2B (average FIC >2). 
Antagonism was less marked with a longer incubation period (72 hours). These 
results were supported in the in vivo study where mice receiving rifampicin and 
chloroquine showed earlier recrudescence and a drop in overall survival. 
In vitro tests showed that omeprazole is mildly antagonistic when 
combined with chloroquine. The in vivo study revealed that for ANKA and NK65 
strains, omeprazole at doses of 5, 10 and 20 mg/kg/day, slightly improves day of 
recrudescence and overall survival figures at the end of a month without reaching 
significance. Effect on rate of decline of parasitemia is very minimal.  
As rifampicin is strongly antagonistic to chloroquine both in vitro and in 
vivo, such combinations should be avoided in clinical practice. It is possible that 
concomitant use of rifampicin in TB patients who also contracted malaria, may 
have helped propagate chloroquine resistance due to the lengthier clearance 
times of the parasite. As neither p-glycoprotein inhibitor is a suitable 
chemosensitizer for chloroquine resistance perhaps a reevaluation of resistance 
mechanisms would expedite the search for a suitable chemoreversal agent. 
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CHAPTER 1 
 
INTRODUCTION 
 
 
1.1  Malaria overview 
 
 Malaria, a parasitic infection transmitted by certain anopheline 
mosquitoes, is one of the most prevalent and pernicious diseases of humans, 
estimated to kill between 700,000 – 2.7 million people (mainly children) 
worldwide each year as shown in Table 1.1. It affects about 5% of the world’s 
population. (Breman, 2001) 
 While Malaysia has one of the oldest malaria control programs in the 
world and large scale eradication programs and vector control measures that 
have resulted in a steep drop in incidence in the nineties, from 2.99/1000 
population in 1994 to 0.56/1000 population in 2000. However despite the general 
success in controlling malaria, it remains an important health issue in remote 
areas. A good majority of cases occur in Sabah where emerging chloroquine 
resistance has been noted. 
 The widespread availability of cheap and effective anti-malarials, 
particularly chloroquine and sulphadoxine-pyrimethamine has curbed the extent 
of mortality and morbidity, but it has also encouraged the development and 
spread of resistance. While many strategies have been offered to counter 
chloroquine resistance, the lack of a truly effective vaccine has spurred 
investigators to intensify the search for cheap and potent new drugs/drug 
combinations to address this need.   
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Table 1.1  Deaths and malaria-related deaths (1,000s)  
Area 
Population
All deaths 
(%) 
Malaria 
deaths (%) 
Malaria/total 
(%) 
World 
Africa 
America 
Eastern 
Mediterranean 
Europe 
Southeast Asia 
Western Pacific 
6,122,210 
655,476 
837,967 
493,091 
874,178 
1,559,810 
1,701,689 
56,554 
10,681 
(18.9) 
5,911 (10.5) 
4,156 (7.3) 
9,703 (17.2) 
14,467 
(25.6) 
11,636 
(20.6) 
1,124 
963 (85.7) 
1 (-) 
55 (4.9) 
0 
95 (8.5) 
10 (0.9) 
2.0 
9.0 
0.02 
1.3 
- 
0.7 
0 
Adapted from the World Health Organization World Health Report, 2002 
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1.2  Malaria lifecycle and clinical manifestations 
 
 There are four species of Plasmodia which infect humans, but 
Plasmodium falciparum accounts for the majority of instances of morbidity and 
mortality. Its virulence and adaptability are important factors which make it a 
deadly threat. While drug resistance for P. vivax has also been noted, this 
phenomenon is nowhere near as widespread as that of P. falciparum. 
  
 The lifecycle of a malarial parasite is a complex one as shown in Figure 
1.1. An infected mosquito injects sporozoites into the blood of the host. 
Sporozoites enter liver cells, multiply and release merozoites into the blood 
stream. Merozoites invade red blood cells and start a phase of multiplication 
where they mature from ring forms to early trophozoites, late trophozoites, 
immature schizonts and mature schizonts which burst to release another batch of 
merozoites; a cycle which can be repeated indefinitely causing malarial 
symptoms. A small portion of merozoites develop sexually into gametocytes 
which are then taken up by mosquitoes when they feed, thus completing the 
cycle.  A summary of various clinical manifestations of malaria is given in Figure 
1.2. 
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Figure 1.1 Lifecycle of Plasmodia 
 
 
 
 
 
 
